Harpula Holdings utilizes advanced data harmonization, analysis, and AI/ML technologies to enhance drug discovery and development processes. The company addresses inefficiencies in patient identification and trial execution, aiming to expedite the delivery of new medicines to patients.
Funding
Funding not disclosed
Founders
Product
Problem
The drug development process faces challenges in efficiently identifying suitable patients for clinical trials and effectively executing these trials, leading to delays in delivering new medicines to patients. The increasing volume and variety of data further complicate efforts to solve complex problems in drug development.
Solution
Harpula Holdings leverages data harmonization, advanced analytics, and AI/ML technologies to address critical pain points in the drug development lifecycle. The company focuses on enhancing patient identification and optimizing trial execution to accelerate the delivery of new medicines. By investing in and developing technology and data-driven solutions, Harpula aims to improve the drug development experience for patients, sites, and sponsors. The company's approach involves harmonizing diverse data sources, applying advanced analytics and visualization techniques, and implementing AI/ML/LLM to generate next-generation insights. Harpula also focuses on collecting unique patient population data assets and leveraging Real World Evidence (RWE) data and capabilities.
Target Audience
Harpula's primary customers include pharmaceutical companies, biotechnology firms, and clinical research organizations involved in drug discovery and development.
Features
- Data harmonization, analysis, and visualization across various data types.
- AI/ML/LLM implementation for advanced insights and solutions.
- Patient identification and trial enhancement strategies.
- Collection of unique patient population data assets.
- Real World Evidence (RWE) data and capabilities.